Article

Second Sight doubles patient enrollment for retinal implant study

Second Sight Medical Products Inc. announced that the FDA has granted approval for up to 20 people who are blind or who have severely impaired vision due to retinitis pigmentosa to participate in a feasibility study for its retinal implant (Argus II Retinal Implant) in the United States. Ten RP volunteers are participating in the U.S. study and an additional 12 RP volunteers are participating in similar studies throughout Europe and Mexico.

Fort Lauderdale, FL-Second Sight Medical Products Inc. announced that the FDA has granted approval for up to 20 people who are blind or who have severely impaired vision due to retinitis pigmentosa to participate in a feasibility study for its retinal implant (Argus II Retinal Implant) in the United States. Ten RP volunteers are participating in the U.S. study and an additional 12 RP volunteers are participating in similar studies throughout Europe and Mexico.

The retinal implant is a three-part system designed to transmit information about the physical environment directly to an individual’s retina-bypassing the photoreceptors that have been damaged due to RP. The device consists of a 60-electrode grid that is implanted surgically and attached to the retina. The electrodes transmit information acquired from an external video camera that is mounted on a pair of eyeglasses worn by study volunteers. The implant has been designed to last for several years, but can be safely removed if necessary, according to the company.

“We are pleased that the FDA has approved our request for increased enrollment of the U.S. cohort of our international clinical trial,” said Robert Greenberg, MD, PhD, president and chief executive officer of Second Sight. “We expect this data to continue to demonstrate a good safety profile with significant efficacy improvements and to move us one step closer to European and U.S. market approvals.”

Six U.S. ophthalmic centers are participating in the study and actively recruiting study volunteers. These centers include the Columbia University Medical Center/Lighthouse International, New York; Doheny Eye Institute, University of Southern California, Los Angeles; Retina Foundation of the Southwest, Dallas; Scheie Eye Institute/Wills Eye Hospital, Philadelphia; University of California, San Francisco; and Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore.

Four major European centers are participating and actively enrolling volunteers in the study. These centers include Central Manchester University Hospital in Manchester, England; Le Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, Paris; Moorfields Eye Hospital, London; and Service d’Ophtalmologie, Hôpital Cantonal Universitaire de Genève, Geneva, Switzerland. The study also is being conducted at Centro de Retina Medica y Quirurgica SC; Centro Medico Puerta de Hierro CUCS; and Universidad de Guadalajara in Guadalajara, Mexico.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
© 2025 MJH Life Sciences

All rights reserved.